Use the hyperlinks, where available to access additional clinical trial information.
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Other Non-Commercial Sponsor
Canteen - Australian Young Cancer Patient Clinical Trials Initiative
In this trial, patients will be randomised to one of four chemotherapy regimens in order to identify which treatment is the best fit for future use. All four arms are currently standard of care treatment options and will be administered as follows:
(Arm 1) Topotecan and Cyclophosphamide (TC): 6 cycles of 21 days, additional cycles at clinician's discretion.
IV Infusoion of Topotecan 0.75mg/m2 and Cyclophosphamide 250mg/m2 on day 1, 2, 3, 4, 5.
(Arm 2) Irinotecan and Temozolomide (IT): 6 cycles of 21 days, additional cycles at clinician's discretion.
IV infusion of Irinotecan 50mg/m2 on days 1, 2, 3, 4, 5
Temozolomide 100mg/m2 orally on days 1, 2, 3, 4, 5
(Arm 3) Gemcitabine and Docetaxel (GD): 6 cycles of 21 days, additional cycles at clinician's discretion.
IV infusion of Gemcitabine 900mg/m2 on days 1, 8.
IV infusion of Docetxal 800mg/m2 on day 8.
(Arm 4) High dose Ifosfamide (IFOS): 4 cycles of 21 days.
IV infusion of Ifosfamide 3g/m2 on days 1, 2, 3, 4, 5.